What you'll learn
- Appraise the benefits and risks of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes mellitus, heart failure and chronic kidney disease
- Formulate a comprehensive pharmacotherapeutic plan to reduce cardiovascular and kidney risk in people with type 2 diabetes mellitus, heart failure and chronic kidney disease
- Describe models for the co-management of people with increased cardiovascular and kidney risk by physicians and pharmacists
This is an accredited, livestreamed course offered by Harvard Medical School as part of the Contemporary Pharmacotherapy: Collaborative Clinical Explorations series. This course is targeted to pharmacists, pharmacy residents, physicians, physician assistants, clinicians, medical residents, nurses and nurse practitioners.
Select the Take Course button to view additional information on the course registration page.
Contact email@example.com with questions.
*Register before September 24 to receive the discounted price.
Harvard Medical School
You may also like
- Review the appropriate dosing and monitoring of NOACs and their appropriate use in different vulnerable patient populations.